Home › Products › Cardiology › Upadoz 30mg Tablet
Upadoz 30mg Tablet
Salt Composition: UPADACITINIB
- Manufacturer: MSN LABORATORIES (INDIA)
- Pack Size: 30 TABLET(s) IN A BOTTLE
- Dosage Form: TABLET
- Strength: 30MG
- Prescription Required
- Storage: Store at room temperature (15–30°C). Keep away from moisture and direct sunlight. Do not use expired or damaged medication. Keep out of reach of children.
₹3579.00₹4209.38
Inclusive of all taxes
Product Introduction
Upadoz 30mg Tablet is a prescription medicine used to treat a variety of autoimmune and inflammatory disorders in adults. It contains Upadacitinib, which belongs to the class of Janus kinase (JAK) inhibitors. This medicine works by blocking specific enzymes involved in immune system signalling, thereby reducing abnormal immune responses. As a result, it helps relieve symptoms such as inflammation, swelling, stiffness, and joint pain. The oral tablet formulation offers a convenient alternative to injectable biologic therapies, providing effective long-term disease management and improving overall quality of life. During treatment with Upadoz 30mg Tablet, regular monitoring of blood cell counts, liver function, and cholesterol levels is recommended, as the medicine may increase the risk of infections, including tuberculosis, herpes zoster (shingles), and pneumonia. This medication should not be used during pregnancy or breastfeeding unless advised by a healthcare professional. Before starting treatment, inform your doctor if you have a history of heart disease, cancer, blood clots, or chronic infections, as these conditions may require additional monitoring or special precautions.
Uses
Treatment of moderate to severe Rheumatoid Arthritis in adults who did not respond well to other medicines. Management of Psoriatic Arthritis in adults with an inadequate response to conventional therapies. Treatment of moderate to severe Atopic Dermatitis in adults who are candidates for systemic therapy. Treatment of active Ankylosing Spondylitis in adults who did not respond adequately to conventional therapies. Treatment of moderately to severely active Ulcerative Colitis in adults who have had an inadequate response or intolerance to other medicines.
How it works
In autoimmune diseases, the body’s immune system becomes overactive and attacks its own tissues, causing inflammation and damage. Upadacitinib inhibits Janus kinase (JAK) enzymes, which are responsible for transmitting signals that activate inflammation. Blocking these signals reduces immune system overactivity, lowers inflammation, and helps control symptoms of chronic inflammatory conditions.
How to Use
Take this medicine exactly as prescribed by your doctor. Usually taken once daily, with or without food. Swallow the tablet whole; do not crush or chew. Your doctor will decide the dose based on your condition and overall health.
Side Effects
Serious: Severe infections (tuberculosis, pneumonia, shingles) Blood clots (in legs or lungs) Chest pain, shortness of breath Severe stomach pain or black stools Allergic reactions (rash, swelling of face/lips, difficulty breathing) Liver problems (yellowing of eyes/skin, dark urine) Common: Nausea Cough Fever Headache Stomach pain Tiredness Upper respiratory tract infections Acne.
Expert Tips
Do not start treatment if you have an active infection. Your doctor may test for tuberculosis and hepatitis before starting therapy. Routine blood tests (liver, kidney, cholesterol, blood counts) are required during treatment. Inform your doctor if you are scheduled for vaccinations, as live vaccines are not recommended while on Upadacitinib. Always take the medicine as directed; do not stop suddenly without consulting your physician.
References
- A Rubbert-Roth et al., “Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis,” The New England Journal of Medicine, [October 2020], demonstrating upadacitinib’s remission rates compared to abatacept in RA patients https://www.nejm.org/doi/full/10.1056/NEJMoa2008250 ?
- R Sanmartí et al., “Upadacitinib for Patients with Rheumatoid Arthritis,” summarizing the phase II BALANCE I & II trials (dose-ranging) and the phase III SELECT trial program for RA regulatory approval https://pmc.ncbi.nlm.nih.gov/articles/PMC10002765/ ?
- GR Burmester et al., “Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease,” Advances in Therapy, [2025], analysing long-term safety across multiple disease indications https://pubmed.ncbi.nlm.nih.gov/36754548/
- C Zhang et al., “Safety profile and dose-dependent adverse events of upadacitinib: a meta-analysis,” Frontiers in Pharmacology, [2025], highlighting dose-related risks such as hepatic disorders, neutropenia, and acne https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1598972/full
Safety Advice
Pregnancy: Consult Your Doctor Upadacitinib may harm the unborn baby. Do not use during pregnancy. Inform your doctor if you are pregnant or planning to conceive.
Lungs: Consult Your Doctor This medication may sometimes cause breathing difficulties, cough, or shortness of breath. Report such symptoms immediately to your doctor.
Breastfeeding: Unsafe Avoid use while breastfeeding, as it may pass into breast milk and harm the infant.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.